| Entries |
| Document | Title | Date |
|---|
| 20080199407 | Drug Detoxification Protocol Using Microdosing - This invention relates to use of an opioid receptor agonist in microdose quantities to reduce or eliminate the withdrawal symptoms associated with discontinuing drug use. The dosage of the agonist is reduced over an extended period of time. | 08-21-2008 |
| 20080247959 | FORM OF ADMINISTRATION SECURED AGAINST MISUSE - The invention relates to a form of administration which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The invention also relates to a method for the production thereof. | 10-09-2008 |
| 20080292558 | COLORED ESMOLOL CONCENTRATE - A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation. In one embodiment, the concentrated esmolol formulation allows identification of the concentrate even after transfer of the concentrate out of a labeled primary container. The concentrated esmolol formulation can include from about 25 to about 1000 mg/ml of esmolol hydrochloride, a buffering agent and a color additive. Any number of color additives may be included such as indocyanine green, phenopheylene, hemoglobin, cyanocobalamine, patent blue, and indigo carmine vitamin B2 and naturally occurring vitamins and minerals. The amount included in the formulation is highly dependent on the color additive selected. The color additive should be included in an amount sufficient to easily distinguish the concentrated esmolol formulation from at least about a 1:4 dilution of the concentrate. Also, a medical product is provided that includes a colored concentrated esmolol housed in a container, and a package housing the container and instructions. The instructions can notify that a color additive has been added to the concentrated esmolol formulation to aid in differentiating it. Additionally a method of allowing easy identification of a concentrated esmolol formulation is provided. The method includes providing a colored concentrated esmolol formulation that has from about 25 to about 1000 mg/ml of esmolol and a color additive. | 11-27-2008 |
| 20080317678 | Laser Marked Dosage Forms - The present invention relates to a coated dosage form having openings to expose the core material or an intermediate coating layer. The invention also relates to methods for manufacturing such coated dosage forms. | 12-25-2008 |
| 20090068116 | Chemical system with self-timing indicator - A luminescent composition, with a luminescent marker and a ionizing agent exhibiting luminescence for an indicatory period once intermixed, and with luminance intensity remaining at a threshold intensity during indicatory period. Luminescence also can be exhibited responsive to responsive to excitatory light applied to the composition. The luminescent marker includes a coumarinic compound and the ionizing agent includes an ammonium base. Antimicrobial agents are included. A luminescence measuring apparatus includes a photoemitter and a photodetector responsive to an emissive light induced by photoemitter. An optical filter can be used with the photodetector. A two-phase composition dispensing apparatus includes a first phase reservoir, a second phase reservoir, a mixing nozzle, and a dispensing mechanism. | 03-12-2009 |
| 20090191132 | Coded medication and methods of preparing same for identification and distinguishment - A selected substance is dissolved into a given injectable fluid medication having an initial clear visual appearance. The selected substance is selected from a group of substances which, when dissolved in the injectable fluid medication, will alter the clear appearance to produce a non-clear or altered visual appearance. The altered visual appearance could be a color, which, by code, identifies the given injectable fluid medication, and distinguishes the given injectable fluid medication from a different injectable fluid medication, the clear visual appearance of which has been altered by dissolving another selected substance to produce a colored visual appearance different from the color of the altered visual appearance of the given injectable fluid medication. | 07-30-2009 |
| 20090304601 | METHOD OF MARKING A COMPOSITION FOR USE IN ORAL ADMINISTRATION - There is provided a marking method that is highly productive and enables production of easily-identifiable compositions for use in oral administration such as drugs and foods without damaging the quality of the oral composition. The marking method according to the present invention is a method for marking such a composition for use in oral administration and includes the steps of: dispersing a change in color-inducing oxide in the composition for use in oral administration; and scanning a surface of the composition for use in oral administration with a laser beam at wavelengths of from 200 nm to 1100 nm and with from 0.1 W to 50 W average power in to make the particles of the change in color-inducing oxide agglomerate so as to become discolored. The change in color-inducing oxide used in the present invention is at least one selected from the group consisting of titanium dioxide, yellow ferric oxide, and red ferric oxide. | 12-10-2009 |
| 20100003198 | Antimicrobial Topical and Other Preparations Containing Fluorescent or Illumination Dye and Tracer Agents or Compounds - A formulation for topical application to human skin and other surface preparation compositions containing antimicrobial, antifungal and antiviral compounds which remain on human skin and other surface compositions to reduce or dominate bacteria, virus and fungi present, prevent future contamination by their presence and substantive character, contain agents or compounds that contain antibacterial, antiviral and antifungal properties and flourescent dyes and tracers that contain illumination properties exhibiting various colons including clear and no color pigment, that when exposed to certain light such as ultraviolet, will produce an illumination effect in various colors including dear and no color for a period of time within a preferred range of thirty minutes to six hours or longer from the time of initial application, and prior to for instance application of ultraviolet light, such flourescent dyes and tracers appear to be clear in color, invisible or have no color pigment showing on the skin or other surfaces, but when exposed to for instance ultraviolet fight, the surface illuminates allowing a person to determine if human skin or other surface has been adequately covered with the antibacterial, antifungal or antiviral composition agent or compound, and to significantly increase the activity to reduce and eliminate bacteria, virus and fungi on the surface, and support programs for antibacterial, antifungal and antiviral quality control, compliance, verification and education for industry and human handwash technique. | 01-07-2010 |
| 20100040557 | Double-layered zaleplon- contained tablet - Disclosed is a double-layered tablet containing zaleplon. The tablet includes an instant release layer and a delayed release layer. The instant release layer contains zaleplon, lactose, maltose, microcrystalline cellulose, sodium lauryl sulfate, and at least one excipient. The delayed release layer contains zaleplon, maltose, microcrystalline cellulose, a polymer, and at least one excipient. A dissolution curve is obtained for the double-layered zaleplon-contained tablet by using a 0.1N hydrochloric acid buffer and pH 6.8 phosphoric acid buffer contained in stirring devices having rotatable blades with stirring speeds of 50-200 RPM, and the release of zaleplon is controlled in such a way to follow the dissolution curve, so as to provide the advantages of improving sleep quality, enhancing safety of medicine use, being convenient to use, and offering flexible dosing. | 02-18-2010 |
| 20100221193 | COLOR CHANGE SURGICAL PREP SOLUTION - This invention discloses a surgical prep solution formulation, either film forming or non-film forming, that changes color upon a change in pH to indicate that the solvent has sufficiently evaporated. The major components of this surgical prep solution include: antimicrobial agents, solvents, pH adjusters, color changing pH indicators, and optionally: film forming polymers, dyes and viscosity regulators. The pH of the solution may rise or fall depending on the pH of the original solution as compared with the normal pH range of the acid mantle of the human skin or the normal pH range of a sterilizing solution. As the pH changes, the pH indicator may cause the surgical prep solution to change color. Concurrently, as the fluids evaporate, the pH indicators interact with atmospheric CO | 09-02-2010 |
| 20100310475 | Biocide Capsules, Preparation Comprising them and Sanitary Pad Comprising the Preparation - The invention is directed to biocide capsule for using it in a biocide preparation, wherein at least one active ingredient is enclosed in the capsules with a wall not dissolving, or dissolving only to a minimal extent in watery environment with a pH range below the cutting pH value, but dissolving in the pH-range over the cutting pH value, and at least one of the wall and the load contains an indicator substance suitable for colour indication. The invention is directed to the biocide preparation containing the vaginal treating substance and the capsules evenly distributed. The preparation is used for healthcare purposes, primarily for killing the pathogens of the body surface, body orifices, open and closed body cavities. The preparation can advantageously be used for the treatment and/or diagnosis of the vagina. | 12-09-2010 |
| 20100322869 | METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED SAFETY PROFILE OVER CONVENTIONAL WARFARIN THERAPY - A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof. | 12-23-2010 |
| 20100322870 | METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY - A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof. | 12-23-2010 |
| 20110052505 | Post-biopsy cavity treatment implants and methods - A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture. | 03-03-2011 |
| 20110081299 | CLEANING AND DISINFECTING AGENT - A detergent and disinfectant in which water-soluble permanganates are used in an alkaline solution in order to initiate the oxidation of organic substances and simultaneously a chemical oxidant, preferably a peroxodisulfate, is used which is capable of producing radical reactions with catalytic support by manganates originating from the supplied permanganate, which reactions produce the oxidation of organic substances. All components are present in powder form and a respective powder mixture can be dissolved rapidly and free from residues in water. It thus represents a universally applicable, highly effective detergent and disinfectant. | 04-07-2011 |
| 20110158916 | Anti-viral tissue product with visual indicator - Anti-viral tissues are provided with a pH indicator which provides the tissue user with a visual indicia, via color changes, that the tissue has active ingredients. Furthermore, the pH indicators can be used to illustrate neutralization of the pH of infected nasal discharge, which has a higher pH than healthy nasal discharge, giving the user a reason to believe that the product is working to deactivate virus. | 06-30-2011 |
| 20110158917 | ANTI-VIRAL TISSUE PRODUCT WITH VISUAL EFFICACY INDICATOR - Anti-viral tissues are provided with a pH indicator which can communicate to a tissue user by means of visual indicia, via color changes, that the tissue has active ingredients. Furthermore, the pH indicators can be used to illustrate neutralization of the pH of infected nasal discharge, which has a higher pH than healthy nasal discharge, giving the user a reason to believe that the product is working to deactivate virus. | 06-30-2011 |
| 20110165090 | METHOD AND COMPOSITION FOR DELIVERY OF MEDICANTS TO ANIMALS - According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method. | 07-07-2011 |
| 20110165091 | METHOD AND COMPOSITION FOR DELIVERY OF MEDICANTS TO ANIMALS - According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method. | 07-07-2011 |
| 20110177010 | Vitamin preparation - Two-phase preparation for temporally gradual administration comprising
| 07-21-2011 |
| 20110182826 | Composition With A Color To Indicate Coverage - A composition comprising at least one indicator, at least one light stabilizer, and at least one antioxidant. The composition is useful as a cleanser that provides a usage timer based on color change to indicate to a person that sufficient time has elapsed for cleansing. | 07-28-2011 |
| 20110182827 | Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent - A dosage form includes a dose of at least one bioactive agent and a substance that is visible to a normal light or to a special light source in the buccal, vaginal, rectal or ostomic cavity of a patient in order for medical personnel to determine if the patient is being compliant with taking medication or that a person is not truthful in denial of taking medication. The substance is either coating the at least one bioactive agent or intermixed with the at least one bioactive agent in a delivering body, and leaves behind a stain in the cavity for a predetermined period for compliance/abuse assessment. | 07-28-2011 |
| 20110217242 | Phenol with color - 1. Liquefied (or Liquified) Phenol USP (Carbolic Acid Liquefied) is Phenol maintained in a liquid condition by the presence of 10.0% water. Its topical medical use includes P & A (Phenol & Alcohol) procedures, and other procedures necessitating an anesthetic antiseptic, solvent, or cauterant. In treating ingrown nails, it is applied to the nail bed to prevent regrowth of nails. As a colorless solution, it can be difficult to see where an application is going during a procedure. Phenol with color eliminates this problem by creating a readily visible way of identifying where the application is going. | 09-08-2011 |
| 20110286939 | OSTEOGENIC COMPOSITIONS CONTAINING A COLORING AGENT - An osteogenic composition is provided for implantation at or near a target tissue site beneath the skin, the osteogenic composition comprising a growth factor and a coloring agent, wherein the coloring agent imparts color to the growth factor to allow the user to see the growth factor at or near the target tissue site. In some embodiments, a method is provided for accelerating bone repair, the method comprising mixing bone morphogenic protein- | 11-24-2011 |
| 20110300080 | ACIDIFIED CHLORITE DISINFECTANT COMPOSITIONS WITH OLEFIN STABILIZERS - A two-part disinfecting systems, as well as disinfecting compositions and methods for making and using the same. The two-part disinfecting system contains a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition, wherein the first part comprises a chlorite and the second part comprises an acid, and wherein the first part, the second part, or both the first and second parts comprise an olefin compound. | 12-08-2011 |
| 20110305642 | MICRONUTRIENT SUPPLEMENT - A micronutrient supplement the supplement being characterized by having at least two types of distinct dosage units wherein said distinct dosage units which physically separate nutritional, vitamin or mineral supplements which are known or proven to be negatively interacting when co-mingled or co-administered, the distinct dosage units being designed to be taken at a predetermined time interval. | 12-15-2011 |
| 20120034171 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form. | 02-09-2012 |
| 20120093736 | REVERSIBLE COLOR-CHANGING INK FORMULATIONS AND NONWOVEN WIPES - A reversible color-changing ink formulation, and a nonwoven wipe to which the ink formulation is securely bound, are provided. The reversible color-changing ink formulation includes about 55-98% by weight of a polymer binder, about 0.1-20% by weight of a reversible color-changing dye that reversibly changes between a first color and a second color at a pH of about 5.5 to about 8.0, and optional amounts of plasticizer, inorganic particulate filler, and color brightener. During use, the nonwoven wipe is impregnated with a sanitizer solution that contains a quaternary ammonium compound. The nonwoven wipe reversibly changes between a first color when impregnated with the sanitizer solution and a second color when the sanitizer solution is depleted during use. The change to the second color indicates the need to recharge the nonwoven wipe with the sanitizer solution, whereupon the first color returns. | 04-19-2012 |
| 20120107250 | ABUSE-PROOFED DOSAGE FORM - An abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof. | 05-03-2012 |
| 20120237452 | Antiseptic Solution of Di(4-Chloro-Phenyldiguanido) Compound And Process Therefor - The present invention relates to a stable antiseptic solution comprising: a di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof, wherein said di(4-chlorophenyldiguanido) compound or a pharmaceutically acceptable salt thereof is a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to a process for preparing said antiseptic solution. | 09-20-2012 |
| 20120282187 | METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED SAFETY PROFILE OVER CONVENTIONAL WARFARIN THERAPY - A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof. | 11-08-2012 |
| 20120301406 | SKIN CARE COMPOSITION WITH INDICATING FUNCTION AND METHOD OF USING THE SAME - A skin care composition with indicating function including a skin care component, a pH indicator and a buffer solution is provided. The skin care composition has a pH value less than or equal to 8. A method of using the skin care composition includes the following. The skin care composition is applied on a skin surface. After the skin care composition is applied on the skin surface for a period of time, the color of the skin care composition changes. When the color of the skin care composition changes, the skin care composition is removed from the skin surface. | 11-29-2012 |
| 20120301407 | METHOD OF TREATING A MAMMALIAN TEAT AND RELATED COMPOSITIONS - A method of treating or protecting a mammalian teat by applying a topical composition to the teat, wherein the topical conditioning composition comprises (a) citrate; (b) methylene blue; and (c) an alkyl para-hydroxybenzoate; as well as related methods and compositions. | 11-29-2012 |
| 20130022552 | BLOOD CLOTTING COMPOSITION AND METHOD OF USE - The composition is a blood clotting composition including at least one hemostatic agent and an indicator agent that adheres to the skin on or around the wound, the indicator agent being specifically identifiable to the hemostatic composition. The composition can be adapted to be applied to a wound as an emergency trauma treatment in homes, public places, trauma treatment centers, at accident locations, in the field of military combat, or any other potential site of severe trauma as a first response to reduce or stop bleeding. The composition can include at least one clotting agent, an analgesic, a bactericide (such as silver), and at least one antibiotic. An applicator device for the composition is included. | 01-24-2013 |
| 20130078190 | ANTI-MICROBIAL HAND TOWEL WITH TIME-DELAY CHROMATIC TRANSFER INDICATOR AND ABSORBENCY RATE DELAY - A disposable paper towel with an anti-microbial lotion and is provided with a chromatic transfer indicator which undergoes a delayed, visually perceptible color change at a predetermined time after the towel is wetted. An anti-microbial lotion on the towel increases water absorbency times (WAR) to further promote lotion transfer to the skin and increase lotion transfer effectiveness. | 03-28-2013 |
| 20130108556 | PHARMACEUTICAL FORM FOR COMBATING CHEMICAL SUBMISSION OF A MEDICAMENT | 05-02-2013 |
| 20130171075 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form. | 07-04-2013 |
| 20130177504 | Nanoscale Particle Formulations and Methods - Provided herein in some embodiments is a formulation comprising (a) one or more nanoscale particle; and (b) a film-forming polymer. In some instances, the formulation is an immediate and sustained released formulation suitable for topical administration or administration to surfaces. Also provided here in certain embodiments is a method of reducing the population of pathogenic microorganisms on skin or surfaces, the method comprising applying to the skin or surface a composition, the composition comprising (a) one or more nanoscale particle; and (b) a film-forming polymer. | 07-11-2013 |
| 20130189191 | Carriers, Formulations, Methods For Formulating Unstable Active Agents For External Application And Uses Thereof - The present disclosure teaches unique formulations for topical administration of tetracycline antibiotics, in which the tetracycline antibiotics remain stable. | 07-25-2013 |
| 20130216483 | DELIVERY SYSTEM FOR REMOTE TREATMENT OF AN ANIMAL - A method of remotely treating an animal including launching a delivery system at the animal, wherein the delivery system comprises a dosage projectile adapted to deliver a biologically active agent to an animal substantially without piercing the skin of the animal and containing a biologically active agent and a transdermal carrier in liquid or gel form, wherein the agent and the carrier are encapsulated in one or more encapsulating agents, and wherein the encapsulating agents forms a frangible shell; impacting the projectile on the animal to release the biologically active agent and the transdermal carrier from the frangible shell substantially without piercing the skin of the animal; and delivering the biologically active agent to the animal, wherein the transdermal carrier facilitates passage of the biologically active agent across the skin of the animal to provide treatment to the animal. | 08-22-2013 |
| 20130315842 | ORAL ANESTHESIA APPLICATION - The present invention provides methods of administering an active agent to a localized mucous membrane in the oral cavity of a mammal, as well as oral dissolving film formed therefore. | 11-28-2013 |
| 20130336899 | ANTIMICROBIAL FORMULATIONS THAT AID IN WOUND HEALING - The invention discloses compositions and formulations for the treatment of clean or infected wounds, some of the inventive formulations can be used to reduce or eliminate microbial contamination from surfaces such as skin, and inanimate objects such as countertops, cooking utensils, medical devices, cookware, food, grooming aids and agricultural biocides, and the like. Some of these compositions and formulations are well suited for use in wound dressings. Some of the formulation can kill and/or inhibit the growth of pathogenic bacteria, fungi, spores and viruses. The formulations comprise a compound such as an osmoticum in high enough concentration to create an osmotic gradient and at least one compound that acts to comprise the integrity of a microorganism's membrane or cell wall. These formulations may optimally include at least one agent that thickens the formulations. In some aspects the formulation is in the form of an emulsion. | 12-19-2013 |
| 20140010765 | MICRONUTRIENT SUPPLEMENT DISPENSING PACKAGE - Provided herein is a prenatal and postpartum multivitamin and mineral supplement package provided in the form of a plurality of solid oral dosage units individually contained in blister packs wherein a portion of the dosage forms are iron-containing while at least half of the dosage units are essentially iron-free and wherein the total amount of iron in the package as sold to purchasers is less than about 1300 mg of elemental iron. | 01-09-2014 |
| 20140086847 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE - The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form. | 03-27-2014 |
| 20140099267 | NEAR INFRARED ABSORBERS - An ink formulation having a marking component and a reduced indium tin oxide (r-ITO) is disclosed. The r-ITO in powder form exhibits a lightness (L*), according to the 1976 CIE (L*, a*, b*) space, of not more than 50. | 04-10-2014 |
| 20140105830 | ABUSE-PROOFED DOSAGE FORM - The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof. | 04-17-2014 |
| 20140170079 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form. | 06-19-2014 |
| 20140205546 | NANOSCALE PARTICLE FORMULATIONS AND METHODS - Provided herein in some embodiments is a formulation comprising (a) one or more nanoscale particle; and (b) a film-forming polymer. In some instances, the formulation is an immediate and sustained released formulation suitable for topical administration or administration to surfaces. Also provided here in certain embodiments is a method of reducing the population of pathogenic microorganisms on skin or surfaces, the method comprising applying to the skin or surface a composition, the composition comprising (a) one or more nanoscale particle; and (b) a film-forming polymer. | 07-24-2014 |
| 20140241997 | WOUND TREATMENT - Use of a moulding composition comprising a polymer and a setting agent for wound debridement, wherein said use comprises adding water to said moulding composition to form a moulding fluid, applying said moulding fluid to a surface of a wound, allowing said moulding fluid to set in contact with said surface to form a solid covering on said surface, followed by removing said solid covering from the wound. The alginate composition adheres strongly to bacterial biofilms on the wound, whereby the biofilms are removed with the alginate composition. The moulding composition may be used in conjunction with a staining agent that undergoes a colour change in the presence of bacteria or bacterial polysaccharides to show the presence and removal of the biofilm. Also provided are methods of treating wounds using the compositions. | 08-28-2014 |
| 20140271491 | ADHESIVE MEDICAL PRODUCTS AND METHODS FOR TREATING GASTROINTESTINAL LESIONS - The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated. | 09-18-2014 |
| 20140286876 | VETERINARY ACTIVE AGENT APPLICATION - The present invention, as described above and as further defined by the claims, provides methods of administering an active agent via adhesion of a film to a mucous membrane in the oral cavity of a mammal, as well as and ODF formed therefore. An active agent may be ingested as the ODF dissolves resulting in systemic treatment of the mammal. In additional embodiments, an ODF may provide topical administration of an active agent. | 09-25-2014 |
| 20140301954 | MUCOUS MEMBRANE ACTIVE AGENT APPLICATION - The present invention provides methods of administering an active agent to a specifically identified area of mucous membrane of a human being, as well as a body dissolving film formed therefore. | 10-09-2014 |
| 20140356294 | DOSAGE THAT IS SAFEGUARDED FROM ABUSE - The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form. | 12-04-2014 |
| 20150044144 | DISINFECTANT SOLUTION - The present invention relates to a disinfectant solution, comprising an oxidative and reductive potential (ORP) solution and a colorant. A disinfectant article, a method of forming the disinfectant solution and use of the disinfectant solution are also provided. | 02-12-2015 |
| 20150056148 | ANTI-MICROBIAL HAND TOWEL WITH TIME-DELAY CHROMATIC TRANSFER INDICATOR AND ABSORBENCY RATE DELAY - A disposable paper towel with an anti-microbial lotion and is provided with a chromatic transfer indicator which undergoes a delayed, visually perceptible color change at a predetermined time after the towel is wetted. An anti-microbial lotion on the towel increases water absorbency times (WAR) to further promote lotion transfer to the skin and increase lotion transfer effectiveness. | 02-26-2015 |
| 20150335757 | COLOURED DISINFECTANT PREPARATION BASED ON BISPYRIDINIUMALKANE - The non-solid disinfectant preparation includes a) bispyridiniumalkane (in particular octenidine) and b) dye selected from xanthene dyes, azo dyes and polyterpene compounds. The preparation is free from fluorescein and salts thereof. The novel preparations exhibit an excellent remanence effect. | 11-26-2015 |
| 20150346172 | APPARATUS WITH TIMED COLOR CHANGE INDICATION - An apparatus with time controlled color change indication comprises an apparatus includes a disposable, limited or restricted use product and an oxygen sensing color changeable dye disposed on a portion of the apparatus, the dye being translucent or having a first color upon application and for a defined time thereafter and the dye changing color after exposure to oxygen for the defined time. For example, a packaging for containing a product for human consumption has a portion with a color changeable dye disposed thereon. The dye changes color after being exposed to oxygen for a controlled and predetermined period of time indicating that the product for human consumption should no longer be consume or has decreased in freshness, quality of taste or potency. | 12-03-2015 |
| 20150359747 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form. | 12-17-2015 |
| 20160015036 | Methods and apparatuses related to pre- and post-dip teat treatment in milking facilities - A novel inexpensive post-dip formulation for the use of chlorine-based post-dip disinfectant. The present invention provides a new pre-dip or post-dip formulation with the following properties: Inexpensive; Easy to produce and mix at the site of application from readily available components; Components which can be delivered in dry form for reduced bulk; Harmless, non-irritating for the teat skin and for the skin of the milkers; Highly effective bactericide in pre and post-dip solutions for mastitis prevention; Yields only environmentally friendly byproducts. | 01-21-2016 |
| 20160015650 | Immediate Release Abuse Deterrent Liquid Fill Dosage Form - The present disclosure relates to an oral, immediate release, abuse deterrent liquid filled capsule containing polyethylene glycol and at least one active pharmaceutical ingredient susceptible to abuse. The dosage form is abuse deterrent to parenteral administration. The present disclosure also relates to processes of preparing the dosage form. | 01-21-2016 |
| 20160022588 | ABUSE-PROOFED ORAL DOSAGE FORM - The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N. | 01-28-2016 |
| 20160022590 | COMPOSITIONS AND METHODS FOR REDUCING OVERDOSE - Drug delivery formulations, uses thereof and methods of making same are provided in order to reduce the potential for abuse, misuse or improper administration of an addictive substance or any active substance and to prevent, reduce, inhibit, or delay purposeful or accidental overdose of an active substance by ingesting too many dosage forms at once, for example. | 01-28-2016 |
| 20160038614 | ORAL ANESTHESIA APPLICATION - The present invention provides a device for administering an active agent to a localized mucous membrane in the oral cavity of a mammal, as well as an oral dissolving film formed therefore. | 02-11-2016 |
| 20160039591 | PACKAGING SYSTEMS, DEVICES, METHODS, AND COMPOSITION INCLUDING CANNABINOID UNIT DOSE FORMS - Systems, devices, methods, and compositions are described for providing, among other things, cannabinoid unit dose forms. Also described are packaging, systems, devices, methods, and compositions including, among other things, phyto-cannabinoid unit dose forms for treating various diseases or disorders. | 02-11-2016 |
| 20160074388 | ABUSE-PROOFED DOSAGE FORM - The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof. | 03-17-2016 |
| 20160089316 | Compound, Composition, Polymer, Mylar Film and Method for Indicating Maximum Exposure to the Sun and UV Radiation - A composition for protecting from ultraviolet radiation is disclosed. The composition comprises a filter and an effectiveness indicator responsive to the reduction of effectiveness protection. | 03-31-2016 |
| 20160106737 | Extended Release Abuse Deterrent Liquid Fill Dosage Form - The present disclosure relates to an oral, extended release, abuse deterrent dosage form containing a controlled release agent, a second agent and/or polyethylene glycol, and at least one active pharmaceutical ingredient susceptible to abuse. The dosage form is stable at high temperatures and abuse deterrent to oral and parenteral administration via dose dumping, extraction, and purification. The present disclosure also relates to processes of preparing the dosage form. | 04-21-2016 |
| 20160150779 | EFFICIENT STABILIZER IN CONTROLLING SELF ACCELERATED DECOMPOSITION TEMPERATURE OF PEROXYCARBOXYLIC ACID COMPOSITIONS WITH MINERAL ACIDS | 06-02-2016 |
| 20160166517 | ABUSE-PROOFED DOSAGE FORM | 06-16-2016 |
| 20160374963 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a dosage that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form. | 12-29-2016 |
| 20190142767 | ABUSE-PROOFED ORAL DOSAGE FORM | 05-16-2019 |
